This document discusses scleroderma (SSc) and its effects on the gastrointestinal (GI) tract. It notes that almost all SSc patients experience GI involvement, with symptoms affecting any part of the GI tract from esophagus to anus. The GI tract is dysfunctional in SSc patients, with slow motility and weak sphincters. Treatment aims to control symptoms, though there are currently no treatments that can stop the progression of GI fibrosis in SSc. The document provides detailed information on how SSc impacts specific areas of the GI tract and potential treatment options.